Amgen (NASDAQ:AMGN) Price Target Raised to $351.00

Amgen (NASDAQ:AMGN) had its price target lifted by equities researchers at Guggenheim from $347.00 to $351.00 in a research report issued to clients and investors on Thursday,MarketScreener reports. The firm presently has a “neutral” rating on the medical research company’s stock. Guggenheim’s target price indicates a potential downside of 0.84% from the stock’s previous close.

Other equities analysts have also issued reports about the stock. Rothschild & Co Redburn raised their price objective on shares of Amgen from $180.00 to $200.00 and gave the company a “sell” rating in a research report on Wednesday, February 18th. Argus raised their price objective on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Jefferies Financial Group initiated coverage on shares of Amgen in a research report on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price objective for the company. Mizuho raised their target price on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Finally, HSBC reaffirmed a “buy” rating and issued a $425.00 target price on shares of Amgen in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $355.16.

Amgen Price Performance

AMGN stock opened at $353.97 on Thursday. The firm has a 50 day moving average of $363.43 and a 200-day moving average of $334.15. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen has a 12 month low of $261.43 and a 12 month high of $391.29. The firm has a market capitalization of $190.81 billion, a P/E ratio of 24.85, a price-to-earnings-growth ratio of 3.45 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the business earned $5.31 earnings per share. Amgen’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, sell-side analysts predict that Amgen will post 20.62 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Old North State Trust LLC grew its holdings in shares of Amgen by 21.6% in the fourth quarter. Old North State Trust LLC now owns 2,568 shares of the medical research company’s stock worth $841,000 after purchasing an additional 456 shares during the last quarter. J. Derek Lewis & Associates Inc. bought a new position in shares of Amgen in the fourth quarter worth approximately $269,000. Purpose Unlimited Inc. bought a new position in shares of Amgen in the fourth quarter worth approximately $1,299,000. Cornerstone Planning LLC bought a new position in shares of Amgen in the fourth quarter worth approximately $2,155,000. Finally, Rockefeller Capital Management L.P. grew its holdings in shares of Amgen by 27.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 642,161 shares of the medical research company’s stock worth $210,186,000 after purchasing an additional 138,577 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Phase III win — Amgen’s subcutaneous TEPEZZA matched IV efficacy and offers faster, potentially more accessible dosing for thyroid eye disease, supporting revenue expansion prospects. AMGN’s Subcutaneous Tepezza Scores Phase III Win in Thyroid Eye Disease
• Positive Sentiment: TEPEZZA on‑body injector data — Phase 3 results for an on‑body injector showed strong efficacy and safety versus IV, suggesting at‑home administration that could broaden uptake amid growing competition. Amgen’s TEPEZZA Injector Data Sparks Questions On Value And Competition
• Positive Sentiment: Analyst upside — RBC raised its price target to $370 and kept an outperform view, signaling increased sell‑side conviction that helps justify the rally. Royal Bank Of Canada Increases Amgen (NASDAQ:AMGN) Price Target to $370.00
• Positive Sentiment: Competitive positioning — Several analyst notes and commentaries argue Amgen’s TEPEZZA data leaves rivals (notably Viridian) on the defensive, reinforcing Amgen’s lead in thyroid eye disease. Viridian Therapeutics: Why Elegrobart Phase 3 Results Fail To Challenge Amgen
• Neutral Sentiment: Cantor Fitzgerald reiteration — Cantor Fitzgerald reaffirmed a neutral rating with a $350 target, reflecting a balanced view on near‑term upside versus longer‑term LT potential. Benzinga coverage of Cantor Fitzgerald rating
• Neutral Sentiment: Investor interest & value angle — Multiple outlets note increased search/attention and highlight Amgen’s value characteristics, keeping it on watchlists for income/value investors. Here’s Why Amgen (AMGN) is a Strong Value Stock
• Negative Sentiment: Morgan Stanley Hold — Morgan Stanley maintained a Hold and set a $309 price target, flagging limited near‑term upside despite acknowledging longer‑term AI/innovation potential; this is a restraint on consensus bullishness. Amgen: Long-Term AI Potential but Limited Near-Term Upside Supports Hold Rating

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.